A Phase 2 interventional study of EMP-01 and EMP-01 Placebo in Social Anxiety Disorder, sponsored by atai Therapeutics, Inc.. Completed at 7 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by atai Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Phobia, Social with a site in United Kingdom — 1 open to participants now, 1 under way, none of them phase 3. Phobia, Social · United Kingdom.
Among the 12 studies in Phobia, Social with a site in United Kingdom, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 2, and was the 12th registered.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
Browse Phobia, Social studies →1 of the 12 studies in Phobia, Social with a site in United Kingdom is open now. Recruiting first, the newest first:
Heriot-Watt University · Sites in United Kingdom
Ages 18–60 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2
First in 2007; this study’s year is marked. 1 started in 2025.
This study's enrollment of 70 is close to the median of 76 across 339 interventional studies indexed under Phobia, Social.
Median enrollment 85 across the 10 interventional studies, 18,212 across the 2 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under atai Therapeutics, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
atai Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Eli Lilly and Company has 2 studies filed under Phobia, Social — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Phobia, Social with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess exploratory efficacy of repeated doses of EMP-01 versus placebo.
This Phase 2, exploratory, multi-center, double-blind, randomized, placebo-controlled trial will enroll approximately 60 adult participants with SAD, randomized 1:1 to receive a total of 2 double-blind administrations of EMP-01 or placebo with a 4-week interval between each administration during the placebo-controlled treatment period. All participants will have their symptoms monitored for 6 weeks until the conclusion of the study. While the primary objective of the study is to assess the safety and tolerability of EMP-01 in participants with SAD, the secondary objective is to estimate any improvement in social anxiety symptoms of participants compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility will be assessed at Screening and will be reconfirmed on Day -1 (Baseline) based on available information, before randomization on the following day (Day 1).
Participants must meet all of the following criteria to be enrolled in this study:
Age
Participants must be between 18 and 65 years of age, inclusive, at the time of signing the ICF.
Disease Characteristics
Clinician Global Impressions - Severity (CGI-S) score ≥ 4 at Screening and Day-1.
Weight
Exclusion Criteria:
Participants who meet any of the following criteria will be excluded from this study:
Medical Conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: EMP-01
Drug: EMP-01 Placebo
EMP-01 capsules
EMP-01 placebo capsules
Incidence and severity of treatment emergent adverse events, adverse events of special interest and serious adverse events.
Assess the safety and tolerability of EMP-01 compared with placebo (PBO) in participants with SAD.
Time frame: Day 1 to EOS [Day 43]
Incidence of clinically significant abnormalities in physical examinations, vital signs, electrocardiogram parameters, and safety laboratory results.
Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.
Time frame: Day 1 [post-dose] to Day 57
Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Assess the safety of EMP-01 compared with placebo (PBO) in participants with SAD.
Time frame: Baseline to Day 57
Liebowitz Social Anxiety Scale (LSAS)
Change from Baseline in the Liebowitz Social Anxiety Scale (LSAS) total score at Day 43 to evaluate the treatment difference in EMP-01 compared with PBO in improving social anxiety symptoms in participants with SAD 6 weeks after initiating treatment.
Time frame: Baseline to EOS [Day 43]
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Dec 2025, 7 months.
Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.